Literature DB >> 32405780

Research Progress of Drug Treatment in Novel Coronavirus Pneumonia.

Junqiang Yan1, Anran Liu2, Jiarui Huang2, Jiannan Wu2, Hua Fan3.   

Abstract

As of March 10, 2020, more than 100,000 novel coronavirus pneumonia cases have been confirmed globally. With the continuous spread of the new coronavirus pneumonia epidemic in even the world, prevention and treatment of the disease have become urgent tasks. The drugs currently being developed are not adequate to deal with this critical situation. In addition to being controlled through effective isolation, we need a rapid response from the healthcare and biotechnology industries to accelerate drug treatment research. By reviewing the currently available literature published at home and abroad, we summarize the current research progress of drug treatment during the epidemic period. At present, the drugs that can be used for treatment mainly include antiviral drugs, antimalarials, glucocorticoids, plasma therapy, biological agents, and traditional Chinese medicine. The effectiveness and safety of drug therapy need to be confirmed by more clinical studies.

Entities:  

Keywords:  drug therapy; novel coronavirus (2019-nCoV); pneumonia; research progress

Mesh:

Substances:

Year:  2020        PMID: 32405780      PMCID: PMC7220569          DOI: 10.1208/s12249-020-01679-z

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  67 in total

Review 1.  Convalescent plasma: new evidence for an old therapeutic tool?

Authors:  Giuseppe Marano; Stefania Vaglio; Simonetta Pupella; Giuseppina Facco; Liviana Catalano; Giancarlo M Liumbruno; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2015-11-06       Impact factor: 3.443

2.  Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia.

Authors:  Hui Li; Shi-Gui Yang; Li Gu; Yao Zhang; Xi-Xin Yan; Zong-An Liang; Wei Zhang; Hong-Yu Jia; Wei Chen; Meng Liu; Kai-Jiang Yu; Chun-Xue Xue; Ke Hu; Qi Zou; Lan-Juan Li; Bin Cao; Chen Wang
Journal:  Influenza Other Respir Viruses       Date:  2017-06-09       Impact factor: 4.380

3.  Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.

Authors:  Ali S Omrani; Mustafa M Saad; Kamran Baig; Abdelkarim Bahloul; Mohammed Abdul-Matin; Amal Y Alaidaroos; Ghaleb A Almakhlafi; Mohammed M Albarrak; Ziad A Memish; Ali M Albarrak
Journal:  Lancet Infect Dis       Date:  2014-09-29       Impact factor: 25.071

4.  Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern.

Authors: 
Journal:  Euro Surveill       Date:  2020-01-31

5.  First Case of 2019 Novel Coronavirus in the United States.

Authors:  Michelle L Holshue; Chas DeBolt; Scott Lindquist; Kathy H Lofy; John Wiesman; Hollianne Bruce; Christopher Spitters; Keith Ericson; Sara Wilkerson; Ahmet Tural; George Diaz; Amanda Cohn; LeAnne Fox; Anita Patel; Susan I Gerber; Lindsay Kim; Suxiang Tong; Xiaoyan Lu; Steve Lindstrom; Mark A Pallansch; William C Weldon; Holly M Biggs; Timothy M Uyeki; Satish K Pillai
Journal:  N Engl J Med       Date:  2020-01-31       Impact factor: 91.245

6.  Clinical management of respiratory syndrome in patients hospitalized for suspected Middle East respiratory syndrome coronavirus infection in the Paris area from 2013 to 2016.

Authors:  A Bleibtreu; S Jaureguiberry; N Houhou; D Boutolleau; H Guillot; D Vallois; J C Lucet; J Robert; B Mourvillier; J Delemazure; M Jaspard; F X Lescure; C Rioux; E Caumes; Y Yazdanapanah
Journal:  BMC Infect Dis       Date:  2018-07-16       Impact factor: 3.090

7.  Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.

Authors:  Xiaolong Tian; Cheng Li; Ailing Huang; Shuai Xia; Sicong Lu; Zhengli Shi; Lu Lu; Shibo Jiang; Zhenlin Yang; Yanling Wu; Tianlei Ying
Journal:  Emerg Microbes Infect       Date:  2020-02-17       Impact factor: 7.163

8.  In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus.

Authors:  Deng-Hai Zhang; Kun-Lun Wu; Xue Zhang; Sheng-Qiong Deng; Bin Peng
Journal:  J Integr Med       Date:  2020-02-20

Review 9.  Diagnosis, treatment, and prevention of 2019 novel coronavirus infection in children: experts' consensus statement.

Authors:  Kunling Shen; Yonghong Yang; Tianyou Wang; Dongchi Zhao; Yi Jiang; Runming Jin; Yuejie Zheng; Baoping Xu; Zhengde Xie; Likai Lin; Yunxiao Shang; Xiaoxia Lu; Sainan Shu; Yan Bai; Jikui Deng; Min Lu; Leping Ye; Xuefeng Wang; Yongyan Wang; Liwei Gao
Journal:  World J Pediatr       Date:  2020-02-07       Impact factor: 9.186

10.  High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa.

Authors:  Hao Xu; Liang Zhong; Jiaxin Deng; Jiakuan Peng; Hongxia Dan; Xin Zeng; Taiwen Li; Qianming Chen
Journal:  Int J Oral Sci       Date:  2020-02-24       Impact factor: 6.344

View more
  1 in total

Review 1.  Will the Use of Pharmacogenetics Improve Treatment Efficiency in COVID-19?

Authors:  Beata Franczyk; Jacek Rysz; Jarosław Miłoński; Tomasz Konecki; Magdalena Rysz-Górzyńska; Anna Gluba-Brzózka
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.